Dapagliflozin 10 MG Oral Tablet [Farxiga]

DRUG3 trials

Sponsors

LM Diagnósticos S.L., Amsterdam UMC, Assistance Publique - Hôpitaux de Paris

Conditions

Acute Kidney InjuryCardiac SurgeryHeart Failure and Chronic Kidney Disease Post-ICUSodium-Glucose Transporter 2 InhibitorType2 Diabetes

Phase 3

Dapagliflozin for Cardio-renal Protection After ICU Discharge

RecruitingNCT07025629

Assistance Publique - Hôpitaux de ParisHeart Failure and Chronic Kidney Disease Post-ICU

Start: 2025-12-02End: 2029-01-15Target: 600Updated: 2026-02-23

Phase 4

Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

LM Diagnósticos S.L.Type2 Diabetes

Start: 2019-04-12End: 2020-02-29Target: 225Updated: 2019-09-03

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2

Active, not recruitingNCT05590143

Amsterdam UMCAcute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor

Start: 2023-06-09End: 2025-09-30Updated: 2025-05-18

Related Papers

Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.

2026-07-30

2799-LB: Does Diabetes Technology Influence Person-Centered Care in the Hospital?

Diabetes2026-06-05

1892-P: Acceptability of Automated Insulin Delivery in the Hospital

Diabetes2026-06-05

Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU).

2026-04-16

Study protocol of the multicentre, randomised, triple-blind, placebo-controlled MERCURI-2 trial: promoting effective renoprotection in cardiac surgery patients by inhibition of sodium glucose cotransporter (SGLT)-2

BMJ Open2025-05-014 citations